October 26, 2008
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796
in Late Breaker Presentation at the 48th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy
October 14, 2008
Paratek to Present Clinical Data in Late Breaker Presentation at the 48th
Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
June 17, 2008
Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Extend and
Expand Drug Discovery Collaboration for Spinal Muscular Atrophy
April 16, 2008
Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance
Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
October 25, 2007
Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to
Finance Programs to Combat MRSA Infections
September 18, 2007
Promising Data from Paratek Pharmaceuticals’ MAR Inhibitor Program Presented in
“Late Breaker” Session at the 47th Interscience Conference on Antimicrobial
Agents and Chemotherapy
July 9, 2007
Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement for
Novel, Narrow-Spectrum Agents for Acne and Rosacea
March 21, 2007
Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Expand Drug
Discovery Collaboration for Spinal Muscular Atrophy
October 2, 2006
Paratek Pharmaceuticals Presents New Preclinical Data on Novel
Aminomethylcycline Antibiotic MK-2764 at 46th Annual ICAAC
May 17, 2006
Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Announce Drug
Discovery Collaboration for Spinal Muscular Atrophy
March 9, 2006
Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for Novel
Antibiotic PTK 0796 Currently in Phase I Testing
July 28, 2005
Paratek Pharmaceuticals Announces Phase I Trial of PTK 0796, a New
Broad-Spectrum Antibiotic.
March 3, 2005
Paratek Expands Management Team with Appointment of John P. Dunphy as CFO.
January 24, 2005
Paratek Announces Presentation at Piper Jaffray's HealthCare Conference.
October 27, 2004
Serono and Paratek Pharmaceuticals in Partnership to Develop A Novel Oral
Treatment for Multiple Sclerosis.
October 27, 2004
Paratek Pharmaceuticals Presents Multiple Sclerosis Data at Society for
Neuroscience Annual Meeting.
September 29, 2004
Paratek Announces New Board Member.
September 23, 2004
Paratek Presentation at UBS Warburg Global Life Sciences Conference to be
Webcast.
July 7, 2004
Paratek Pharmaceuticals To Expand Malaria Program Under Two-Year NIH Phase II
SBIR Grant.
May 3, 2004
Bayer and Paratek Pharmaceuticals Present New Data on First Antibiotic in New
Class, Aminomethylcyclines (AMCs), at 14th Annual ECCMID.
March 24, 2004
Paratek Pharmaceuticals Inc. at Wells Fargo Securities Healthcare Conference.
February 24, 2004
Paratek Pharmaceuticals and Medicines for Malaria Venture Collaborate To
Discover Novel Antimalarial Compounds.
December 3, 2003
Paratek Issued U.S. Patents Covering Methods of Preparing Substituted
Tetracyclines.
November 17, 2003
Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Announce
Partnership to Find a Treatment for Spinal Muscular Atrophy.
October 29, 2003
Paratek Appoints Vice President of Manufacturing and Executive Director For
Clinical Research.
September 15, 2003
Bayer and Paratek Pharmaceuticals Sign Collaboration Agreement for the Novel
Antibiotic BAY73-6944/PTK 0796
May 19, 2003
Paratek to Present at the 103rd General Meeting of the American Society for
Microbiology
October 29, 2002
Paratek Pharmaceuticals To Discuss Lead Candidate Tetracycline at MassOpps 4th
Annual Investor Conference
October 3, 2002
Paratek Pharmaceuticals to Present at UBS Warburg Conference
September 3, 2002
Paratek Pharmaceuticals Awarded NIH Grant To Search For Novel Anti-Malarial
Tetracyclines
August 12, 2002
Paratek Hires Director of Regulatory Affairs
July 23, 2002
Paratek Issued U.S. Patent Covering Second Genetic Target In Fight Against
Microbial Multiple-Drug Resistance
June 10, 2002
Paratek Pharmaceuticals Chairman and Co-Founder Dr. Walter Gilbert Receives
Heritage Award at BIO 2002
June 7, 2002
Paratek Pharmaceuticals to Present at BIO 2002 Business Forum
May 28, 2002
Paratek Pharmaceuticals Completes Final Closing of $30.4 Million Financing
April 9, 2002
Paratek Pharmaceuticals Appoints AOL Time Warner Vice Chairman Kenneth J.
Novack to Board of Directors
December 17, 2001
Paratek Pharmaceuticals Presents Anti-Malarial Advances with Novel
Tetracyclines at ICAAC 2001
November 14, 2001
Anti-Infectives Developer Paratek Pharmaceuticals Hires Veteran Lead
Optimization Chemist
October 29, 2001
Paratek Pharmaceuticals to Present at Massachusetts Biotech Council Conference
October 9, 2001
Paratek Pharmaceuticals to Present at UBS Warburg Conference
Paratek Pharmaceuticals CEO Thomas J. Bigger Talks to The Wall Street
Transcript
July 30, 2001
Paratek Publishes “The Crystal Structure of the Escherichia coli MarR
Protein” in Nature Structural Biology
June 25, 2001
Paratek Pharmaceuticals BIO2001 Presentation Scheduled for Live Webcast
June 21, 2001
Paratek Inks Additional Research Collaboration for Tetracycline Program
Researching Activity Against Resistant Tuberculosis
April 17, 2001
Paratek Appoints Dennis Molnar Executive Director of Corporate Development
March 30, 2001
Paratek Pharmaceuticals to Present at Thomas Weisel Partners Healthcare
Tailwinds Conference 2001
February 27, 2001
Paratek Appoints Dr. Ken Tanaka Vice President of Research and Development
January 16, 2001
Paratek and GlaxoSmithKline See in the New Year with Milestone in Battle
Against Antibiotic Resistance
November 20, 2000
Paratek Pharmaceuticals CEO Presents Vision for Conquering Antibiotic
Resistance
October 17, 2000
Paratek Pharmaceuticals, Inc. Appoints Beverly Armstrong as Chief Financial
Officer
June 27, 2000
Paratek Pharmaceuticals Completes $20 Million Financing
|
